Wilmington, DE, United States of America

Changsheng Zheng

This inventor holds 21 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 5 EPO patents, primarily in Chemokine Receptor Modulation. Top assignees: Incyte Corporation, Bristol-Myers Squibb Pharma Company, Pfizer Corporation. Active years: 2003-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Changsheng Zheng. Retrieved from https://idiyas.com/inventor/changsheng-zheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 4)

% Patents Active = 66.7

CIPO Patents = 3

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 6.8

ph-index = 5

Forward Citations = 104(Granted Patents)

Location History:

Wilmington, DE (US) (2003 - 2014)
Cray, NC (US) (2022)
Cary, NC (US) (2013 - 2024)

Company Filing History:

Bristol-Myers Squibb Pharma Company

Years Active: 2003-2024

Loading Chart...

Areas of Expertise:

Pim Kinase Inhibitor

Chemokine Receptors

Purinone Derivatives

3-Aminopyrrolidine

Cycloalkylaminopyrrolidine

3-Aminocyclopentanecarboxamides

Piperidine Amides

N-Ureidoalkyl-Piperidines

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12043614 - Salts of a Pim kinase inhibitor (2024-07-23),

2. 11505540 - Salts of a Pim kinase inhibitor (2022-11-22),

3. 8729063 - 3-aminopyrrolidine derivatives as modulators of chemokine receptors (2014-05-20),

4. 8703783 - Purinone derivatives as HM74A agonists (2014-04-22),

5. 8697870 - 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors (2014-04-15),

6. 8563582 - 3-aminocyclopentanecarboxamides as modulators of chemokine receptors (2013-10-22),

7. 8470827 - 3-aminocyclopentanecarboxamides as modulators of chemokine receptors (2013-06-25),

8. 8362003 - 3-aminopyrrolidine derivatives as modulators of chemokine receptors (2013-01-29),

9. 8039478 - Purinone derivatives as HM74A agonists (2011-10-18),

10. 7902205 - Purinone derivatives as HM74A agonists (2011-03-08),

11. 7863285 - Purinone derivatives as HM74A agonists (2011-01-04),

12. 7618970 - 3-aminocyclopentanecarboxamides as modulators of chemokine receptors (2009-11-17),

13. 7576089 - 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors (2009-08-18),

14. 7511050 - Purinone derivatives as HM74A agonists (2009-03-31),

15. 7462624 - Purinone derivatives as HM74a agonists (2008-12-09),

Title: Changsheng Zheng: Innovator in Pim Kinase Inhibitor Patents

Introduction: Changsheng Zheng, based in Wilmington, DE, is a prolific inventor with a remarkable portfolio of 21 patents to his name. His work primarily focuses on the development of pharmaceutical compounds aimed at treating various diseases, including cancer. Zheng’s inventions have made significant contributions to the field of medicinal chemistry and cancer treatment.

Latest Patents: Among his latest inventions are the salts of a Pim kinase inhibitor, specifically targeting the compound N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide. These patents include methods of preparation and intermediates, indicating their application in treating Pim kinase-related diseases, particularly cancer.

Career Highlights: Changsheng Zheng has lent his expertise to notable pharmaceutical companies, including Incyte Corporation and Bristol-Myers Squibb Company. His innovative contributions have been pivotal in advancing research and development within these organizations, reflecting his commitment to improving medical outcomes through research-driven solutions.

Collaborations: Throughout his career, Zheng has collaborated with esteemed colleagues, including Chu-Biao Xue and Ganfeng Cao. These collaborations highlight the importance of teamwork and shared knowledge in driving innovation and achieving breakthroughs in the medical field.

Conclusion: Changsheng Zheng stands out as a key player in the realm of pharmaceutical innovation. With his extensive patent portfolio and collaborations with leading companies, he continues to push the boundaries of what's possible in the treatment of complex diseases like cancer. His dedication to research exemplifies the spirit of innovation that drives progress in healthcare.

Profile summary based on public USPTO records.